{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T13:56:34Z","timestamp":1773323794375,"version":"3.50.1"},"reference-count":32,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2012,11,1]],"date-time":"2012-11-01T00:00:00Z","timestamp":1351728000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,11,1]],"date-time":"2012-11-01T00:00:00Z","timestamp":1351728000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2012,11]]},"DOI":"10.1016\/j.urolonc.2010.09.001","type":"journal-article","created":{"date-parts":[[2010,12,17]],"date-time":"2010-12-17T04:26:52Z","timestamp":1292560012000},"page":"813-820","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Treatment of invasive bladder cancer with conformal hypofractionated accelerated radiotherapy and amifostine (HypoARC)"],"prefix":"10.1016","volume":"30","author":[{"given":"Marianthi","family":"Panteliadou","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandra","family":"Giatromanolaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stavros","family":"Touloupidis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evagelia","family":"Destouni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pelagia G.","family":"Tsoutsou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Panagiotis","family":"Pantelis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ioannis","family":"Abatzoglou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyriaki","family":"Sismanidou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael I.","family":"Koukourakis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.urolonc.2010.09.001_bib1","doi-asserted-by":"crossref","first-page":"3061","DOI":"10.1200\/JCO.2002.11.027","article-title":"Combined-modality treatment and selective organ preservation in invasive bladder cancer: Long-term results","volume":"20","author":"Rodel","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2010.09.001_bib2","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0360-3016(97)00579-8","article-title":"Efficacy of radiochemotherapy with platin derivatives compared to radiotherapy alone in organ-sparing treatment of bladder cancer","volume":"40","author":"Sauer","year":"1998","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.urolonc.2010.09.001_bib3","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.ijrobp.2009.04.050","article-title":"A 10-year retrospective review of a nonrandomized cohort of 458 patients undergoing radical radiotherapy or cystectomy in Yorkshire, UK","volume":"77","author":"Munro","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.urolonc.2010.09.001_bib4","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1097\/COC.0b013e31818b9486","article-title":"Bladder conservation treatment in the elderly population: Results and prognostic factors of muscle-invasive bladder cancer","volume":"32","author":"Tran","year":"2009","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.urolonc.2010.09.001_bib5","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.ijrobp.2007.06.030","article-title":"Similar treatment outcomes for radical cystectomy and radical radiotherapy in invasive bladder cancer treated at a United Kingdom specialist treatment center","volume":"70","author":"Kotwal","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.urolonc.2010.09.001_bib6","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.urolonc.2006.09.015","article-title":"Long-term outcome of radiation-based conservation therapy for invasive bladder cancer","volume":"25","author":"Chung","year":"2007","journal-title":"Urol Oncol"},{"key":"10.1016\/j.urolonc.2010.09.001_bib7","doi-asserted-by":"crossref","first-page":"5536","DOI":"10.1200\/JCO.2006.07.6729","article-title":"Trimodality treatment and selective organ preservation for bladder cancer","volume":"24","author":"R\u00f6del","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2010.09.001_bib8","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/0167-8140(91)90033-D","article-title":"Dose fractionation and tumor repopulation in radiotherapy for bladder cancer","volume":"21","author":"Maciejewski","year":"1991","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.urolonc.2010.09.001_bib9","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.ijrobp.2004.02.056","article-title":"Clinical radiobiology of stage T2\u2013T3 bladder cancer","volume":"60","author":"Majewski","year":"2004","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.urolonc.2010.09.001_bib10","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/S0360-3016(98)00263-6","article-title":"Muscle-invasive bladder cancer treated with external beam radiation: Influence of total dose, overall treatment time, and treatment interruption on local control","volume":"42","author":"Moonen","year":"1998","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.urolonc.2010.09.001_bib11","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.radonc.2004.11.003","article-title":"A randomized trial of accelerated radiotherapy for localized invasive bladder cancer","volume":"75","author":"Horwich","year":"2005","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.urolonc.2010.09.001_bib12","doi-asserted-by":"crossref","first-page":"365","DOI":"10.2307\/3574272","article-title":"The inactivation of Chinese Hamster cells by X-rays: The effect of chemical modifiers on single and double events","volume":"64","author":"Chapman","year":"1975","journal-title":"Radiat Res"},{"key":"10.1016\/j.urolonc.2010.09.001_bib13","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1016\/j.ijrobp.2005.09.023","article-title":"Radical radiotherapy for invasive bladder cancer: What dose and fractionation schedule to choose?","volume":"64","author":"Pos","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.urolonc.2010.09.001_bib14","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/S0167-8140(96)01893-2","article-title":"Hypofractionated radiotherapy for invasive bladder cancer","volume":"43","author":"Scholten","year":"1997","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.urolonc.2010.09.001_bib15","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1053\/clon.1999.9075","article-title":"Hypofractionated radiotherapy for patients with carcinoma of the bladder","volume":"11","author":"Jose","year":"1999","journal-title":"Clin Oncol"},{"key":"10.1016\/j.urolonc.2010.09.001_bib16","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1634\/theoncologist.5-6-471","volume":"5","author":"Kaufman","year":"2000","journal-title":"Oncologist"},{"key":"10.1016\/j.urolonc.2010.09.001_bib17","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.urology.2006.09.064","article-title":"Radical hypofractionated accelerated radiotherapy with cytoprotection for invasive bladder cancer","volume":"69","author":"Koukourakis","year":"2007","journal-title":"Urology"},{"key":"10.1016\/j.urolonc.2010.09.001_bib18","first-page":"2437","article-title":"Individualization of the subcutaneous amifostine dose during hypofractionated\/accelerated radiotherapy","volume":"26","author":"Koukourakis","year":"2006","journal-title":"Anticancer Res"},{"key":"10.1016\/j.urolonc.2010.09.001_bib19","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/0167-8140(95)90055-1","article-title":"LENT SOMA tables","volume":"35","year":"1995","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.urolonc.2010.09.001_bib20","article-title":"Concurrent administration of liposomal doxorubicin improves the survival of patients with invasive bladder cancer undergoing hypofractionated accelerated radiotherapy (HypoARC)","author":"Panteliadou","year":"2010","journal-title":"Med Oncol"},{"key":"10.1016\/j.urolonc.2010.09.001_bib21","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0360-3016(00)00663-5","article-title":"A Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: First report of RTOG 9003","volume":"48","author":"Fu","year":"2000","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.urolonc.2010.09.001_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijrobp.2009.07.1691","article-title":"A prospective phase III randomized trial of hypofractionation vs. conventional fractionation in patients with high-risk prostate cancer","author":"Arcangeli","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.urolonc.2010.09.001_bib23","doi-asserted-by":"crossref","first-page":"147","DOI":"10.2174\/157488709789957583","article-title":"Accelerated hypofractionated radiotherapy schedules in breast cancer: A review of the current literature","volume":"4","author":"Kalogeridi","year":"2009","journal-title":"Rev Recent Clin Trials"},{"key":"10.1016\/j.urolonc.2010.09.001_bib24","first-page":"161","article-title":"Continuous hyperfractionated accelerated radiotherapy (CHART) vs. conventional radiotherapy in non-small-cell lung cancer: A randomized multicenter trial","volume":"350","author":"Saunders","year":"1997","journal-title":"CHART Steering Committee Lancet"},{"key":"10.1016\/j.urolonc.2010.09.001_bib25","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.ijrobp.2003.10.018","article-title":"Radiotherapy for muscle-invasive carcinoma of the bladder: Results of a randomized trial comparing conventional whole bladder with dose-escalated partial bladder radiotherapy","volume":"59","author":"Cowan","year":"2004","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.urolonc.2010.09.001_bib26","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1016\/S0360-3016(03)00187-1","article-title":"Protective effect of amifostine during fractionated radiotherapy in patients with pelvic carcinomas: Results of a randomized trial","volume":"56","author":"Athanassiou","year":"2003","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.urolonc.2010.09.001_bib27","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1016\/S0360-3016(03)00660-6","article-title":"Subcutaneous administration of amifostine (ethyol) is equivalent to intravenous administration in a rat mucositis model","volume":"57","author":"Cassatt","year":"2003","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.urolonc.2010.09.001_bib28","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S0167-8140(03)00019-7","article-title":"Concomitant boost radiotherapy for muscle invasive bladder cancer","volume":"68","author":"Pos","year":"2003","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.urolonc.2010.09.001_bib29","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/S0360-3016(03)00718-1","article-title":"RTOG 97\u201306: Initial report of a phase I-II trial of selective bladder conservation using TURBT, twice-daily accelerated irradiation sensitized with cisplatin, and adjuvant MCV combination chemotherapy","volume":"57","author":"Hagan","year":"2003","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.urolonc.2010.09.001_bib30","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1053\/j.seminoncol.2003.11.014","article-title":"Amifostine: Is there evidence of tumor protection?","volume":"30","author":"Koukourakis","year":"2003","journal-title":"Semin Oncol"},{"key":"10.1016\/j.urolonc.2010.09.001_bib31","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1002\/ijc.1592","article-title":"Inhibition of spontaneous metastases formation by amifostine","volume":"97","author":"Grdina","year":"2002","journal-title":"Int J Cancer"},{"key":"10.1016\/j.urolonc.2010.09.001_bib32","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/s00262-002-0342-y","article-title":"Amifostine protects lymphocytes during radiotherapy and stimulates expansion of the CD95\/Fas and CD31 expressing T-cells in breast cancer patients","volume":"52","author":"Koukourakis","year":"2003","journal-title":"Cancer Immunol Immunother"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143910002504?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143910002504?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T09:58:21Z","timestamp":1761040701000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143910002504"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,11]]},"references-count":32,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2012,11]]}},"alternative-id":["S1078143910002504"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2010.09.001","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2012,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment of invasive bladder cancer with conformal hypofractionated accelerated radiotherapy and amifostine (HypoARC)","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2010.09.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}